000			nab a22 7a 4500
999			_c16652 _d16652
003			PC16652
005			20211108134325.0
008			211108b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_91207 _aCastellano Tortajada, Gregorio _eAparato Digestivo
100			_92292 _aAlonso Manzano, María Luisa _eAparato Digestivo
245	0	0	_aValor del FibroScan® en el seguimiento de los pacientes con infección crónica por virus B sin indicación de tratamiento. _h[artículo]
260			_bGastroenterología y hepatología, _c2014
300			_a37 Suppl 2:15-21.
500			_aFormato Vancouver: Castellano G, Manzano ML. Valor del FibroScan® en el seguimiento de los pacientes con infección crónica por virus B sin indicación de tratamiento. Gastroenterol Hepatol. 2014 Jul;37 Suppl 2:15-21.
501			_aPMID: 25087707
504			_aContiene 23 referencias
520			_aTransient elastography (TE) is a noninvasive method of assessing hepatic fibrosis in a quick, simple and reproducible manner. FibroScan is the best-known elastography apparatus and can assess a tissue volume 100 times greater than hepatic biopsy. Given that it lacks complications, TE can be repeated in the follow-up visit, thereby providing evolutionary information. One of its limitations, however, is its failure rate (4.5% of examinations), mainly in obese patients. TE has certain characteristics in chronic hepatitis B (HBV) infection. Transaminase levels and necroinflammation increase in reactivations, with hepatic stiffness increasing by 1.2 to 4.4 times. The second characteristic is related to macronodular cirrhosis caused by HBV, with less fibrous tissue compared with that produced by hepatitis C. Therefore, the cutoff values are smaller for hepatitis B than for hepatitis C. FibroScan helps categorize patients with chronic HBV infection into 4 fibrosis groups (approximate mean values and adding 1-2 more points with high transaminase levels): not significant (<6 kPa), grey area (6-9 kPa), significant (>9 kPa) and cirrhosis (>12 kPa). Thus, Fibroscan contributes to the treatment decision, and its repeated use during treatment enables us to verify that fibrosis has not progressed. In cases with no indication for treatment (chronic hepatitis with no criteria, inactive carrier state, immune-tolerant), the periodic reapplication of TE helps determine whether the inactivity continues or not. If the results are compatible with cirrhosis, hepatocarcinoma surveillance should be started.
710			_9273 _aServicio de Medicina del Aparato Digestivo
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16652.pdf _ySolicitar documento
942			_2ddc _cART _n0